Peripheral pterygium, stationary, bilateral
ICD-10 H11.043 is a billable code used to indicate a diagnosis of peripheral pterygium, stationary, bilateral.
Peripheral pterygium, stationary, bilateral, is characterized by a benign growth of conjunctival tissue that extends onto the cornea, typically arising from the nasal or temporal limbus. Clinically, patients may present with a fleshy, triangular-shaped growth that can cause cosmetic concerns and potential visual disturbances if it encroaches on the visual axis. The anatomy involved includes the conjunctiva, cornea, and sclera, with the pterygium affecting the anterior segment of the eye. Disease progression is generally slow, and while stationary, it can become symptomatic due to irritation or inflammation. Diagnostic considerations include a thorough ocular examination, where the growth's size, location, and any associated symptoms such as redness or dryness are assessed. Differential diagnoses may include pinguecula or other conjunctival lesions. Management typically involves monitoring for changes, and surgical intervention may be considered if the pterygium becomes symptomatic or progresses significantly. Accurate diagnosis and coding are essential for appropriate treatment and reimbursement.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
H11.043 specifically covers bilateral peripheral pterygium that is stationary. It does not include pterygium that is recurrent or associated with significant visual impairment.
H11.043 should be used when both eyes are affected by stationary pterygium, distinguishing it from unilateral cases or those that are active or recurrent.
Documentation should include a comprehensive eye examination report detailing the presence of bilateral pterygium, its size, location, and any associated symptoms, along with treatment plans.
